CARL D. REGILLO, MD, FACS (Chair)
Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Mid Atlantic Retina/Retina Service at Wills Eye
Director, Wills Eye Hospital Retina Service
Philadelphia, Pennsylvania
DAVID S. BOYER, MD
Clinical Professor of Ophthalmology
Keck School of Medicine
University of Southern California
Senior Partner
Retina-Vitreous Associates Medical Group
Los Angeles, California
JAY S. DUKER, MD
Director, New England Eye Center
Professor and Chair
Department of Ophthalmology
Tufts University School of Medicine
Boston, Massachusetts
Target Audience
The educational design of this activity addresses the needs of retina specialists.
Statement of Need/Program Overview
With much focus on the initial treatment of neovascular age-related macular degeneration (AMD), there is a need to develop long-term plans for disease that responds to initial therapy or demonstrates a suboptimal response to initial treatment. However, the complexity of treatment regimens and volume of new data from clinical trials investigating novel neovascular AMD signaling pathways requires time to research and apply to practice. The purpose of this activity is to update retina specialists on current and emerging strategies for long-term management of patients with neovascular AMD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Choose individualized treatment plans based on available guidelines and clinical data for patients with advanced AMD
- Review newer technology for screening of neovascular AMD
- Recognize the clinical relevance of new data on current and emerging therapies
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and MedEdicus LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or CME@globaleducationgroup.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must pass the post test with a minimum score of 70% and complete the evaluation/application for credit.
PC | MAC |
---|---|
Microsoft Windows 2000 SE or above | MAC OS 10.2.8 |
Flash Player Plugin (v7.0.1.9 or greater) | Flash Player Plugin (v7.0.1.9 or greater) |
Internet Explorer (v5.5 or greater), or Firefox | Safari |
Adobe Acrobat Reader* | Adobe Acrobat Reader* |
Internet Explorer is not supported on the Macintosh. | |
* Required to view printable (PDF) version of the lesson |
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter | Reported Financial Relationship |
---|---|
David S. Boyer, MD | Consultant/Independent Contractor: Aerpio Therapeutics; Alcon; Allegro Ophthalmics, LLC; Allergan; Bausch & Lomb Incorporated; F. Hoffmann-La Roche Ltd; Genentech, Inc; Novartis AG; Ohr Pharmaceutical; Optovue, Incorporated; Ora, Inc; Regeneron Pharmaceuticals, Inc; River Vision; ThromboGenics NV; and TLC Laser Eye Centers; Speakers’ Bureau: Allergan; Stock Shareholder: Allegro Ophthalmics, LLC; and Ohr Pharmaceutical |
Jay S. Duker, MD | Consultant/Independent Contractor: Alcon; Allergan; Aura; Bayer AG; Ironwood Pharmaceuticals, Inc; and Santen Pharmaceutical Co, Ltd; Grant/Research Support: Optovue, Incorporated; Topcon Medical Systems, Inc; and Zeiss; Stock Shareholder: Hemera Biosciences; Other/Royalty: Eleven Biotherapeutics; and pSivida |
Carl D. Regillo, MD, FACS | Consultant/Independent Contractor: Aerpio Therapeutics; Alcon; Allergan; Bayer AG; Genentech, Inc; Iconic Therapeutics, Inc; and Notal Vision; Grant/Research Support: Alcon; Allergan; Astellas Pharma US, Inc; Bayer AG; Genentech, Inc; GlaxoSmithKline; Iconic Therapeutics, Inc; Novartis AG; and Regeneron Pharmaceuticals, Inc |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager | Reported Financial Relationship |
---|---|
Ashley Marostica, RN, MSN | Nothing to disclose |
Lindsay Borvansky | Nothing to disclose |
Andrea Funk | Nothing to disclose |
Cheryl Guttman Krader | Nothing to disclose |
Diane McArdle, PhD | Nothing to disclose |
Cynthia Tornallyay, RD, MBA, CHCP | Nothing to disclose |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MedEdicus LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This CME activity is copyrighted to MedEdicus LLC ©2017. All rights reserved.